top of page

GPCR Retreat Program

Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease

Date & Time

Friday, November 3rd / 9:20 AM

Abstract


Coming Soon

About Ali Salahpour


"Dr. Salahpour did his undergrad (1993-1996) and PhD (1996-2002) at University of Montreal in the Department of Biochemistry. His PhD work was under the supervision of Dr. Michel Bouvier working on the topic of GPCR dimerization/oligomerization. In November of 2002, he joined the lab of Dr. Marc Caron at Duke University for his post-doctoral training. In the Caron lab, Dr. Salahpour worked on Dopamine Transporter and its role on regulating dopamine transmission and homeostasis. In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has continued working on dopamine transmission and homeostasis and the role of several of key modulators of the dopamine system, including the dopamine transporter (DAT), the Vesicular Monoamine Transporter 2 (VMAT2), Tyrosine Hydroxylase (TH) and Trace Amine Associate Receptor 1 (TAAR1)."



Ali Salahpour on the web


Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec


22nd GPCR Retreat Sponsored by


 

Canada Research Chairs
U of Ottawa
Dr. GPCR
Canadian Institutes of Health Research
Bristol Myers Squibb
InversAgo Pharma
Monica Seger and Family
Duke University, Dept. Cell Biology
OHRI Neurosciences Program
University of Toronto Mississauga
Domain Therapeutics NA Inc.
Otsuka Pharmaceuticals
McGill University, Dept. Pharmacol & Exp Ther
University of Toronto, Dept. of Physiology
Hotchkiss Brain Institute,University of Calgary
OHRI
Université de Montréal, VP Office
Find Therapeutics
University of Toronto, Dept. Pharmacol & Toxicol
Deep Apple
University of Illinois at Chicago (Mark Rasenick)
uOttawa, VP Research Office
American Society of Pharmacology and Experimental Therapeutics
University of Western Ontario Schulich School of Medicine & Dentistry
Heliyon
Université de Sherbrooke, Dept. Pharmacology-Physiology
Research Institute McGill Univ. Health Centre
adMare Bioinnovations
Superluminal
Université de Montréal, Faculty of Medicine
Université de Sherbrooke, Institut de Pharmacologie
Science Signaling
Montana Molecular
IRIC
uOttawa, Dept. Cellular & Molecular Medicine
uOttawa, Dept. Biochem Microbiol Immunol
uOttawa, Behavioral & Physiology Core
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page